Several other equities analysts have also recently issued reports on the company. Deutsche Bank assumed coverage on Humana in a report on Thursday, September 12th. They issued a hold rating and a $300.00 price objective for the company. Morgan Stanley reissued a buy rating and issued a $360.00 price target (up from $337.00) on shares of Humana in a report on Monday, November 18th. Cantor Fitzgerald upgraded shares of Humana from a neutral rating to an overweight rating and raised their price target for the company from $300.00 to $345.00 in a research report on Monday, August 12th. BMO Capital Markets cut shares of Humana from an outperform rating to a market perform rating and cut their price objective for the company from $345.00 to $290.00 in a report on Monday, September 30th. Finally, SunTrust Banks upped their price objective on shares of Humana to $350.00 and gave the stock a hold rating in a research report on Friday, November 15th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $324.82.
Shares of NYSE:HUM traded up $0.30 during trading on Wednesday, hitting $344.42. The stock had a trading volume of 37,392 shares, compared to its average volume of 1,205,448. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.46. Humana has a 12-month low of $225.65 and a 12-month high of $346.80. The stock has a market capitalization of $45.19 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.46 and a beta of 0.90. The stock has a 50-day simple moving average of $313.68 and a two-hundred day simple moving average of $281.85.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a net margin of 4.06% and a return on equity of 22.32%. The company had revenue of $16.24 billion for the quarter, compared to the consensus estimate of $16.15 billion. During the same quarter in the prior year, the company earned $4.58 EPS. Humana’s quarterly revenue was up 14.3% on a year-over-year basis. As a group, sell-side analysts forecast that Humana will post 17.77 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. The ex-dividend date is Monday, December 30th. This represents a $2.20 annualized dividend and a yield of 0.64%. Humana’s dividend payout ratio (DPR) is currently 15.12%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Next Capital Management LLC purchased a new stake in shares of Humana in the second quarter worth about $27,000. Endurance Wealth Management Inc. raised its position in shares of Humana by 354.5% in the 3rd quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock worth $26,000 after purchasing an additional 78 shares during the last quarter. Penserra Capital Management LLC bought a new position in Humana in the 3rd quarter worth about $31,000. Quest Capital Management Inc. ADV bought a new position in Humana in the 3rd quarter worth about $30,000. Finally, Advantage Investment Management LLC lifted its holdings in shares of Humana by 287.1% during the 2nd quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after buying an additional 89 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: Preferred Stock
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.